Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

Takeda begins development of COVID-19 plasma therapy

Drug will harness the antibodies of recovered coronavirus patients

- PMLiVE

US piles pressure on Mallinckrodt over alleged Acthar fraud

Drugmaker allegedly underpaid rebates owed to Medicaid

- PMLiVE

Allergan and Editas claim a CRISPR first in inherited blindness study

Partners are first to use CRISPR to edit cells inside the body

- PMLiVE

Keytruda hits primary endpoint in confirmatory lymphoma trial

Interim analysis demonstrates improvement in progression-free survival

Roche Basel Switzerland

China backs use of Roche’s Actemra for coronavirus

Anti-inflammatory drug will be used in patients with lung complications

- PMLiVE

Q&A: Mike Dixon

PME interviews the CEO of the Healthcare Communications Association (HCA)

HARNESSING TECHNOLOGY TO TRANSFORM HEALTHCARE IN THE DIGITAL AGE

THE IMPACT OF TECHNOLOGY IN HEALTHCARECutting-edge technology is rapidly changing the healthcare landscape. When you look closely at the rate and level of innovation brought about by tech over the...

Say Communications

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

Keeping calm and carrying on: COVID-19 and approaches to CME/CPD during a viral outbreak

Celeste Kolanko, Managing Director, Liberum OPEN Health

OPEN Health

- PMLiVE

Alnylam scores EU approval for RNAi drug Givlaari

Company says it will work towards value-based agreements for the drug

- PMLiVE

BMS partners with Voluntis to co-develop oncology digital therapeutics

Aims to create a mobile app to help patients self-manage their symptoms

- PMLiVE

AbbVie says Allergan takeover delayed by FTC verdict

Merger now likely to complete in second quarter rather than first

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links